Fluorinated Chitosan To Enhance Transmucosal Delivery of Sonosensitizer-Conjugated Catalase for Sonodynamic Bladder Cancer Treatment Post-intravesical Instillation

Li, Guangzhi; Wang, Shupeng; Deng, Dashi; Xiao, Zhisheng; Dong, Ziliang; Wang, Zhiping; Lei, Qifang; Gao, Shan; Huang, Guangtao; Zhang, Enpu; Zeng, Guohua; Zhong, Wen; Wu, Song; Liu, Zhuang

doi:10.1021/acsnano.9b06689

Cited by 180 publications

(149 citation statements)

References 40 publications

Supporting

Mentioning

136

Contrasting

Order By: Relevance

“…bonded catalase with the TCPP sonosensitizer and then allowed it to self‐assemble with fluorinated chitosan to form CAT‐TCPP/FCS nanoparticles for enhanced SDT ( Figure A). [ 100 ] The encapsulated catalase was demonstrated to greatly improve their bioavailability and provided great assistance for the SDT‐induced production of ROS. Accordingly, the weakened hypoxia signals observed in tumors from mice treated with CAT‐TCPP/FCS evidenced the greatly enhanced level of tumor oxygenation in the CAT‐TCPP/FCS group compared with other control groups (Figure 13B).…”

Section: Sonodynamic Therapy Combined With Other Treatmentsmentioning

confidence: 99%

Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Ultrasound (US)-triggered sonodynamic therapy (SDT), as a promising noninvasive therapeutic modality, has received ever-increasing attention in recent years. Its specialized chemical agents, named sonosensitizers, are activated by low-intensity US to produce lethal reactive oxygen species (ROS) for oncotherapy. Compared with phototherapeutic strategies, SDT provides many noteworthy opportunities and benefits, such as deeper penetration depth, absence of phototoxicity, and fewer side effects. Nevertheless, previous studies have also demonstrated its intrinsic limitations. Thanks to the facile engineering nature of nanotechnology, numerous novel nanoplatforms are being applied in this emerging field to tackle these intrinsic barriers and achieve continuous innovations. In particular, the combination of SDT with other treatment strategies has demonstrated a superior efficacy in improving anticancer activity relative to that of monotherapies alone. Therefore, it is necessary to summarize the nanomaterial-assisted combinational sonodynamic cancer therapy applications. Herein, the design principles in achieving synergistic therapeutic effects based on nanomaterial engineering methods are highlighted. The ultimate goals are to stimulate the design of better-quality combined sonodynamic treatment schemes and provide innovative ideas for the perspectives of SDT in promoting its future transformation to clinical application.

show abstract

Section: Sonodynamic Therapy Combined With Other Treatmentsmentioning

confidence: 99%

Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[ 22 ] Most of sonosensitizers are derived from PSs, including porphyrin and its derivatives. [ 23,24 ] For instance, Endo et al. used porphyrin‐like derivatives such as ALA and PpIX for the SDT of gliomas, confirming that combining SDT with porphyrin‐like derivatives can lead to cell apoptosis in vitro.…”

Section: Introductionmentioning

confidence: 99%

An Ultrasound‐Excitable Aggregation‐Induced Emission Dye for Enhanced Sonodynamic Therapy of Tumors

Zeng

Yang

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Ultrasound (US)‐triggered sonodynamic therapy (SDT) can significantly solve the problem of tissue penetrability of light of photodynamic therapy (PDT) that has long vexed physicians in clinics. However, there is a great shortage of sonosensitizers for SDT. Currently, several photosensitizers and their derivatives have been reported for SDT but these dyes are usually quenched when aggregated due to aggregation‐caused quenching (ACQ) effect. In this work, aggregation‐induced emission (AIE) dye (TTMN) assembled nanoparticles (S‐AIE) are synthesized and employed as sonosensitizers for enhanced SDT due to the unique properties of the AIE dye and the deep tissue penetration of ultrasound. Results show that S‐AIE can generate potent singlet oxygen (1O2) under US irradiation to induce cancer cells apoptosis and clearly inhibit tumor growth in vitro and in vivo. In particular, the intrinsic fluorescence of AIE dye can guide the procedure of SDT. To the best of current knowledge, this is the first demonstration of AIE dyes being used as sonosensitizers for SDT and importantly, this work could inspire other more efficient AIE dyes for being used as sonosensitizers for SDT of deep‐seated tumors.

show abstract

“…[ 1 ] During SDT, oxygen plays a determining role in facilitating the generation of sufficient ROS to induce cell apoptosis by lipid peroxidation of mitochondrial and cellular membranes. [ 1g,h,2 ] However, due to the oxygen‐insufficient (hypoxic) tumor microenvironment (TME) inside solid tumors, the efficacy of SDT may be limited. [ 3 ] Moreover, to achieve the optimal therapeutic effects, repeated dosing of therapeutic agents by systemic administration is often required, which would easily lead to exacerbation of side effects and patient incompliance.…”

Section: Introductionmentioning

confidence: 99%

Thermo‐Triggered In Situ Chitosan‐Based Gelation System for Repeated and Enhanced Sonodynamic Therapy Post a Single Injection

She

Zhou

Zhang

et al. 2020

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Sonodynamic therapy (SDT) by utilizing ultrasonic waves triggers the generation of reactive oxygen species (ROS) with the help of sonosensitizers to destruct deep‐seated tumors has attracted great attention. However, the efficacy of SDT may not be robust enough due to the insufficient oxygen supply within solid tumors. Additionally, repeated injections and treatments, which are often required to achieve the optimal therapeutic responses, may cause additional side effects and patient incompliance. Herein, a thermo‐triggered in situ hydrogel system is developed in which catalase (CAT) conjugated with sonosensitizer meso‐tetra (4‐carboxyphenyl) porphine (TCPP) is mixed into chitosan (CS) and beta‐glycerol phosphate disodium (GP) to form the precursor solution. After injection of the precursor solution into tumors, the in situ sol–gel transformation will occur as triggered by the body temperature, resulting in the localized tumor retention of TCPP‐CAT. The locally restrained TCPP‐CAT not only produces ROS under ultrasonic treatment, but also sustainably reverses the oxygen‐deficient status in solid tumors by triggering the O2 generation from the decomposition of endogenous H2O2, further promoting the efficacy of SDT. As a result, the repeated SDT after a single dose injection of such a hydrogel can offer robust treatment effects to effectively eradicate tumors.

show abstract

Fluorinated Chitosan To Enhance Transmucosal Delivery of Sonosensitizer-Conjugated Catalase for Sonodynamic Bladder Cancer Treatment Post-intravesical Instillation

Cited by 180 publications

References 40 publications

Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy

Recent Advances in Nanomaterial‐Assisted Combinational Sonodynamic Cancer Therapy

An Ultrasound‐Excitable Aggregation‐Induced Emission Dye for Enhanced Sonodynamic Therapy of Tumors

Thermo‐Triggered In Situ Chitosan‐Based Gelation System for Repeated and Enhanced Sonodynamic Therapy Post a Single Injection

Contact Info

Product

Resources

About